Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bronchodine is a combination oral syrup containing the opioid codeine and the expectorant guaifenesin. While traditionally indicated for the symptomatic treatment of non-productive cough, it is notably used in clinical research settings, such as those at KU Leuven, as a model agent to induce opioid-induced gastroparesis. By activating mu-opioid receptors in the enteric nervous system, the codeine component significantly delays gastric emptying and alters motility patterns. This pharmacological induction of gastric dysfunction serves as a controlled baseline for evaluating novel diagnostic technologies, including intragastric balloon pressure sensors designed to monitor gastric contractility and volume changes in patients with motility disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + guaifenesin.